Topamax Cleft Palate: FDA Announces Heightened Risk

Recently, the U.S. Food and Drug Administration (FDA) announced new data suggesting that Topamax (topiramate) and its generic versions increase the risk for an infant to be born with the birth defects cleft palate and cleft lip if their mother used the medication during pregnancy. However, it is important to note that women who are currently taking Topamax or any of its generic forms should not stop doing so unless directed by a healthcare professional, even if they are pregnant. Ceasing a 25 mg, 100 mg, or 200 mg dosage of Topamax can cause severe health problems.

Topamax is used in treatment for certain kinds of seizures in people who have epilepsy. The drug is also approved to be used to prevent migraine headaches. The FDA reports the drug has been used for unapproved uses for other conditions which may not be considered to be serious.

Collectively referred to as oral clefts, cleft palate and cleft lip are birth defects that occur when parts of a fetus’ lip or palate do not fuse together completely in the early part of the first trimester of a woman’s pregnancy. Most women are not aware that they are pregnant during the first trimester, thus making the potential risk of Topamax cleft palate all the more hazardous.

As more news and information about Topamax birth defects becomes available, the Topamax oral cleft defect lawyers at Anapol Weiss will keep our readers updated. Be sure to check back with our blog this month as we discuss this dangerous drug and Topamax birth defects. If you have any questions regarding whether you have a Topamax lawsuit, call our injury attorneys today at 1-866-735-2792 for a free consultation.

Contact Information